Article Figures & Data
Figures
- FIGURE 1.
Chemical structures of CP724,714 (A), 125I- or 131I-labeled CP724,714 (B), and its analog (C).
- FIGURE 2.
(A) HER2 and EGFR protein levels in different cells evaluated by Western blot. (B) Binding of 131I-IBA-CP to cells with different levels of HER2 expression (cell line vs. normalized cell-associated radioactivity and effect of preincubation with IBA-CP on binding. Data are mean ± SD (n = 3). (C) Representative results of competition-binding assay using MDA-MB-453 cells. (D) Representative results of saturation assay using MDA-MB-453 cells. NSB = nonspecific binding; SB = specific binding; TB = total binding. ***P < 0.001.
- FIGURE 3.
(A and B) Representative SPECT/CT images obtained 1, 2, 3, and 4 h after injection of 125I-IBA-CP in mice bearing MDA-MB-453 (A) and MCF-7 (B) tumors (circled). (C and D) Respective tumor-to-muscle ratios obtained from images in A and B. n = 4; error bars correspond to SD.
- FIGURE 4.
(A) Representative SPECT/CT images obtained 3 h after injection of 125I-IBA-CP in mice bearing MDA-MB-453 tumors (circled) with or without blocking dose of nonradioactive compound IBA-CP or erlotinib. (B) Quantification of SPECT imaging results. Data are mean ± SD (n = 4). T/M = tumor-to-muscle ratio. ***P < 0.001.
- FIGURE 5.
(A) Biodistribution of 131I-IBA-CP in MDA-MB-453 (HER2-positive), MDA-MB-468 (HER2-negative, EGFR-positive), and MCF-7 (HER2-negative) tumor–bearing mice 3 h after injection and in MDA-MB-453 tumor–bearing mice coinjected with nonradioactive compound IBA-CP or erlotinib as blocking agent 30 min after injection. (B) 131I-IBA-CP tumor uptake from A. (C) 131I-IBA-CP tumor-to-muscle ratio from A. Data are mean ± SD (n = 4). T/M = tumor-to-muscle ratio. ***P < 0.001.
Additional Files
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- No citing articles found.